MTOR and meningioma: Among these targets, mTOR is of particular interest because the efficacy of everolimus, an inhibitor of mTOR, for progressive meningioma was demonstrated in combination with octreotide, a somatostatin analog, in a phase II clinical trial with encouraging findings [6].